Citations

Clear

590 citation(s) found for "Ho, Ben".

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma
Mattarollo, Stephen R. , West, Alison C., Steegh, Kim, Duret, Helene, Paget, Christophe , Martin, Ben P., Matthews, Geoffrey M. , Shortt, Jake , Chesi, Marta , Bergsagel, P. Leif , Bots, Michael, Zuber, Johannes , Lowe, Scott W. , Johnstone, Ricky W. , Smyth, Mark J. , Bergsagel, P. Leif

Mayo Clinic

Blood | August 30, 2012 | Volume: 120 | Issue: 15 | Pages: 3019-3029

10.1182/blood-2012-04-426643 | PMID 22932803 Get It

AbstractImmunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating α-galactosylceramide (α-GalCer) that targets the immune adjuvant properties of NKT cells. In the Eμ-myc transgenic mouse model, single therapeutic vaccination of irradiated, α-GalCer–loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12–dependent production of IFN-γ. CD4 T cells, gamma/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-γ and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-γ. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AML-ETO9a acute myeloid leukemia. Replacing α-GalCer with β-mannosylceramide resulted in prolonged protection against Eμ-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogene-driven lymphomas, and this work supports clinical investigation of NKT cell–based immunotherapy in patients with hematologic malignancies.
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome
Hurley, Paula J. , Marchionni, Luigi , Simons, Brian W. , Ross, Ashley E. , Peskoe, Sarah B. , Miller, Rebecca M., Erho, Nicholas , Vergara, Ismael A. , Ghadessi, Mercedeh , Huang, Zhenhua , Gürel, Bora , Davicioni, Elai , Jenkins, Robert B. , Berman, David M. , Schaeffer, Edward M. , Park, Ben Ho , Platz, Elizabeth A. , Davicioni, Elai

Mayo Clinic

Proceedings of the National Academy of Sciences | August 27, 2012 | Volume: 109 | Issue: 37 | Pages: 14977-14982

10.1073/pnas.1203525109 | PMID 22927397 Get It

Prostate cancer is the second leading cause of cancer death among United States men. However, disease aggressiveness is varied, with low-grade disease often being indolent and high-grade cancer accounting for the greatest density of deaths. Outcomes are also disparate among men with high-grade prostate cancer, with upwards of 65% having disease recurrence even after primary treatment. Identification of men at risk for recurrence and elucidation of the molecular processes that drive their disease is paramount, as these men are the most likely to benefit from multimodal therapy. We previously showed that androgen-induced expression profiles in prostate development are reactivated in aggressive prostate cancers. Herein, we report the down-regulation of one such gene, Sparcl1 , a secreted protein, acidic and rich in cysteine (SPARC) family matricellular protein, during invasive phases of prostate development and regeneration. We further demonstrate a parallel process in prostate cancer, with decreased expression of SPARCL1 in high-grade/metastatic prostate cancer. Mechanistically, we demonstrate that SPARCL1 loss increases the migratory and invasive properties of prostate cancer cells through Ras homolog gene family, member C (RHOC), a known mediator of metastatic progression. By using models incorporating clinicopathologic parameters to predict prostate cancer recurrence after treatment, we show that SPARCL1 loss is a significant, independent prognostic marker of disease progression. Thus, SPARCL1 is a potent regulator of cell migration/invasion and its loss is independently associated with prostate cancer recurrence.
Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer
Li, Ding, Shen, Dong , Wallis, John W., Tine, Brian Andrew Van, Crowder, Robert J., Snider, Jacqueline, Koboldt, Daniel C. , Schierding, William , McMichael, Joshua F. , Kandoth, Cyriac , Wendl, Michael C. , DeSchryver, Katherine, Allred, D. Craig, Unzeitig, Gary, Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, J. Michael, Leitch, Marilyn , Tao, Yu , Fulton, Lucinda , Fulton, Robert S. , Oberkfell, Ben, Du, Feiyu, Demeter, Ryan, Vickery, Tammi L. , McDonald, Sandra , Dooling, David J., Ota, David M., Chang, Li‐Wei , Bose, Ron , Wilson, Richard K. , Ellis, Matthew J. , Luo, Jingqin , Suman, Vera J. , Hoog, Jeremy , Ballman, Karla V. , Chen, Ken , Miller, Christopher A. , Lu, Charles , Harris, Christopher , McLellan, Michael D. , Esserman, Laura J. , Hunt, Kelly K. , Olson, John A. , Harrison, Michelle , Griffith, Malachi , Watson, Mark A. , Ley, Timothy James , Mardis, Elaine R.

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-423-LB-423

10.1158/1538-7445.am2012-lb-423 Get It

Abstract Background: Estrogen receptors are over-expressed in around 70% of breast cancer cases. The genetic changes that occur during aromatase inhibitor (AI) treatment are not well understood and may differ depending upon the patient's response phenotype. Methods: We performed whole genome sequencing (WGS) of matched blood, pre-treatment, and post-treatment biopsy samples from 22 estrogen receptor positive breast cancer patients treated with neoadjuvant aromatase inhibitors. For 5 cases, we performed the whole genome sequencing (WGS) on patients’ matched normal, two pre AI-treatment, and two post AI-treatment DNA isolates from biopsy samples. We validated all putative coding and non-coding somatic mutations using deep sequencing. By comparing the validated somatic mutations from pre- and post- AI treatment biopsy samples, we were able to determine the alterations in the tumor genomes. In every case we defined the clonal architecture of each pair of pre-treatment and post-treatment biopsy samples by comparing the variant allele frequencies from thousands of validated somatic mutations. Results: Comparisons of the two pre AI-treatment biopsy samples from the same patient indicates that the variant allele frequencies of mutations showed high concordances in all 5 cases, 0.74 to 0.95 range of correlation coefficient. Only a small percentage of somatic mutations were detected in one pre-treatment sample and not the other (4.65% overall). In comparing the somatic variations between pre-treatment and matched post-treatment biopsy samples in 22 cases, we found that patients with good clinical response to AI treatment retained known driver mutations only in their pre-treatment tumors. Conversely, those patients with poor clinical response presented new driver mutations in their post-treatment samples. Furthermore, the variant allele frequency for most mutated genes decreased in post AI treatment samples for patients with good AI treatment response; on the contrary, the variant allele frequency increased for patients with poor clinical response. Conclusions: From WGS of matched normal, pre-treatment, and post-treatment biopsy samples, we identified new driver genes mutated in patients with poor clinical response, while patients with good clinical response had lost mutated driver genes in their post-treatment biopsy samples. The genetic landscape revealed by WGS of pre-treatment and post-treatment biopsy samples reveals mutational repertoires are remodeled by AI therapy. This finding suggests deep sequencing of AI treated samples will be necessary to reveal the complete complement of mutations present in a patient's tumor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-423. doi:1538-7445.AM2012-LB-423
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Barreyro, Laura , Will, Britta , Bartholdy, Boris , Zhou, Li , Todorova, Tihomira I. , Stanley, Robert , Parekh, Samir , Pellagatti, Andrea , Boultwood, Jacqueline , Paietta, Elisabeth , Ketterling, Rhett P. , Cripe, Larry D., Fernández, Hugo F. , Greenberg, Peter L. , Tallman, Martin S. , Mitsiades, Constantine S. , Verma, Amit , Steidl, Ulrich , Verma, Amit , Ben‐Neriah, Susana , Montagna, Cristina , Steidl, Christian , Will, Britta , Ketterling, Rhett P , Boultwood, Jacqueline , Parekh, Samir

Mayo Clinic

Blood | June 22, 2012 | Volume: 120 | Issue: 6 | Pages: 1290-1298

10.1182/blood-2012-01-404699 | PMID 22723552 Get It

AbstractCellular and interpatient heterogeneity and the involvement of different stem and progenitor compartments in leukemogenesis are challenges for the identification of common pathways contributing to the initiation and maintenance of acute myeloid leukemia (AML). Here we used a strategy of parallel transcriptional analysis of phenotypic long-term hematopoietic stem cells (HSCs), short-term HSCs, and granulocyte-monocyte progenitors from individuals with high-risk (−7/7q−) AML and compared them with the corresponding cell populations from healthy controls. This analysis revealed dysregulated expression of 11 genes, including IL-1 receptor accessory protein (IL1RAP), in all leukemic stem and progenitor cell compartments. IL1RAP protein was found to be overexpressed on the surface of HSCs of AML patients, and marked cells with the −7/7q− anomaly. IL1RAP was also overexpressed on HSCs of patients with normal karyotype AML and high-risk myelodysplastic syndrome, suggesting a pervasive role in different disease subtypes. High IL1RAP expression was independently associated with poor overall survival in 3 independent cohorts of AML patients (P = 2.2 × 10−7). Knockdown of IL1RAP decreased clonogenicity and increased cell death of AML cells. Our study identified genes dysregulated in stem and progenitor cells in −7/7q− AML, and suggests that IL1RAP may be a promising therapeutic and prognostic target in AML and high-risk myelodysplastic syndrome.
Left Ventricular Hemodynamics Before and 1 Year After Internal Mammary Artery Implantation in Patients with Coronary Artery Disease and Angina Pectoris
McCallister, Ben D., Richmond, David, Saltups, A., Hallermann, Franz J., Wallace, Robert B. , Frye, Robert L.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 42 | Issue: 3 | Pages: 471-477

10.1161/01.cir.42.3.471 | PMID 5451232 Get It

Left ventricular hemodynamics at rest and during supine exercise were studied before and 1 year after internal mammary artery implantation in 24 patients with severe coronary artery disease and angina pectoris and in five similar patients before and after 1 year of medical treatment. In the surgical group, 14 had evidence of one or more implants providing collaterals to coronary arteries, and 10 had no evidence of collaterals from the implant. Only two patients, both with functioning implants, showed a return to normal of left ventricular end-diastolic pressure at rest and during exercise. There was no correlation between clinical improvement and hemodynamics at the time of the postoperative study. It is concluded that left ventricular hemodynamics may return to normal after internal mammary artery implantation but this was uncommon in the present study.
Comparative Quantitative Analysis of the Electrocardiogram and the Vectorcardiogram
McConahay, David R., McCallister, Ben D., Hallermann, Franz J., Smith, Ralph E.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 42 | Issue: 2 | Pages: 245-259

10.1161/01.cir.42.2.245 | PMID 4247020 Get It

Simultaneously recorded standard electrocardiograms (ECG) and Frank vectorcardiograms (VCG) were correlated with the coronary arteriograms and the left ventriculograms of 210 patients. Quantitative criteria were applied to ECG measurements made by manual technics and to VCG measurements obtained by computer technics. As the extent of significant arteriographic disease increased, the frequency of ECG and VCG evidence of "definite" myocardial infarction (MI) increased. The VCG was diagnostic of MI in a greater number of patients than the ECG (50 versus 39, P < 0.01) and excelled in the detection of multiple areas of infarction in a greater number of patients (13 versus six, P < 0.05). This increased sensitivity was gained in anterior, inferior, and true posterior infarcts. Excluding patients with myocardiopathy, all MIs diagnosed from the VCG and all but one from the ECG were associated with significant arteriographic disease in the distribution of the predicted nutrient artery. Quantitative VCG analysis appears superior to the usual ECG analysis in the accurate detection of MI. When MI is diagnosed by either technic, significant associated coronary artery disease can be anticipated in a predictable anatomic distribution.
Left Ventricular Performance During Mild Supine Leg Exercise in Coronary Artery Disease
McCallister, Ben D., Yipintsoi, Tada, Hallermann, Franz J., Wallace, Robert B. , Frye, Robert L.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 37 | Issue: 6 | Pages: 922-931

10.1161/01.cir.37.6.922 | PMID 4968176 Get It

Left ventricular (LV) performance was studied during mild exercise (100 kg-m/min for 3 minutes) in 19 cases of coronary artery disease (CAD). Each patient suffered from a severe anginal syndrome. None had ventricular aneurysm, cardiomegaly, or clinical heart failure. Mean resting values follow: LV end-diastolic pressure (LVEDP), 19 ± 7 mm Hg; LV systolic pressure (LVSP), 150 ± 16 mm Hg; stroke volume index (SVI), 48 ± 10 ml/beat/m 2 ; and LV stroke work index (LVSWI), 81 ± 19 g-m/m 2 . During exercise LVEDP rose to 30 ± 8 mm Hg ( P ≤0.001) and LVS to 160 ± 20 (not significant [NS]); SVI diminished to 46 ± 11 (NS) and LVSWI, to 76 ± 24 (NS). Patients with decreased or asynchronous areas of LV myocardium identified on cine left ventriculograms had higher mean LVEDPs during exercise than did those with normal ventriculograms (34 ± 10 versus 26 ± 4 mm Hg; P ≤0.05). The difference between responses to exercise of patients who experienced angina during the study and of those who did not was NS. Administration of nitroglycerin reduced the increase in LVEDP during exercise. An abnormality in LV performance-a significant rise in LVEDP without a significant increase in SVI or LVSWI-was observed in 13 of 19 cases of CAD.
Temporary Transvenous Catheter-Electrode Pacing of the Heart
Tancredi, Robert G., McCallister, Ben D., Mankin, Harold T.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 36 | Issue: 4 | Pages: 598-608

10.1161/01.cir.36.4.598 | PMID 6041872 Get It

Experience with 110 separate periods of transvenous cardiac pacing by means of a catheter-electrode in 91 patients has been reviewed. Indications for the use of the catheter-electrode included (1) complete heart block with and without Adams-Stokes syndrome, (2) other arrhythmias with and without cardiogenic syncope, (3) malfunction of previously implanted permanent pacemaker units, and (4) need for pacing during general surgical procedures in patients with a variety of rhythm disturbances. A case illustrating the combined use of drug therapy and catheter-electrode pacing in controlling paroxysmal ventricular tachycardia is presented. Only six deaths occurred in spite of the serious heart disease in all 91 patients in this series. Two were related to complications of temporary transvenous intracardiac pacing. The major complications associated with the procedure included perforation of the heart, bacteremia, acute myocardial infarction, cephalic vein phlebitis, and ventricular tachyarrhythmia. Minor problems were primarily related to equipment failure or positional difficulties with the catheter-electrode and were usually of no serious consequence.
Prognosis of myocardial infarctions involving more than 40% of the left ventricle after acute reperfusion therapy.
McCallister, Ben D., Christian, Timothy F. , Gersh, Bernard J. , Gibbons, Raymond J.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 88 | Issue: 4 | Pages: 1470-1475

10.1161/01.cir.88.4.1470 | PMID 8403294 Get It

BACKGROUND Prior studies based on autopsy data suggest that infarction of more than 40% of the left ventricle necessitates cardiogenic shock and death. METHODS AND RESULTS Technetium-99m Sestamibi tomography was used prospectively to measure infarct size at discharge in 166 patients with acute myocardial infarction. Patients with previous myocardial infarction or revascularization were excluded from the trial. Sixteen patients were identified with final infarct sizes > 40% of the left ventricle despite acute reperfusion therapy. These 16 patients (13 men) had a mean age of 63 +/- 10 years; 44% had a previous history of angina. Ten patients had emergent coronary angioplasty only (mean time to percutaneous transluminal coronary angioplasty [PTCA], 6.0 +/- 3.0 hours); 6 had thrombolysis (mean time to tissue plasminogen activator, 4.0 +/- 1.5 hours), of which 2 had rescue PTCA (5 and 3 hours from onset of pain). Of 15 patients who had angiograms after therapy, 15 had open infarct-related arteries. The left anterior descending artery was the infarct-related artery in 14 (9 proximal and 5 distal lesions). Half the patients had only single-vessel disease. Infarct size measured 50 +/- 7% of the left ventricle (range, 42% to 68%). Ejection fraction by radionuclide angiogram was 0.33 +/- 0.09 and 0.38 +/- 0.07 at discharge and 6 weeks, respectively. Hospital complications included shock (1 patient), pulmonary edema (2), angina (3), symptomatic nonsustained ventricular tachycardia (1), transient complete heart block (2), and transient bifascicular block (1). At follow-up (13 +/- 9 months), the patient with shock had died, but the remaining 15 patients were asymptomatic (1 had late PTCA for angina). CONCLUSIONS In the interventional and thrombolytic era, patients with large residual myocardial infarctions can survive without heart failure.